---
type: "Topics"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/topics/38882306.md"
description: "$Recursion Pharmaceuticals(RXRX.US) Many people haven't realized it yet, but this news proves that its underlying logic is viable. Feedback from real end-payers is of great significance to the stock."
datetime: "2026-02-25T14:21:45.000Z"
locales:
  - [en](https://longbridge.com/en/topics/38882306.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/38882306.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/38882306.md)
author: "[夜航星](https://longbridge.com/zh-HK/profiles/12228888.md)"
---

> 支持的語言: [English](https://longbridge.com/en/topics/38882306.md) | [简体中文](https://longbridge.com/zh-CN/topics/38882306.md)


# $Recursion Pharmaceuticals(RXRX.US) Many people ha…


### 相關股票

- [Recursion Pharmaceuticals (RXRX.US)](https://longbridge.com/zh-HK/quote/RXRX.US.md)

## 評論 (2)

- **ʕ•ﻌ•ʔ · 2026-02-26T02:15:16.000Z**: Another 300 million share issuance plus equity incentives, you're really playing it well.Look at the four medical investment conferences in March, shall we? Currently, it's still in a sideways consolidation.
- **Felix的证券 · 2026-02-26T00:42:31.000Z**: Feedback from the actual end payers? What does that refer to? Milestone payments? That's been around for a while, nothing new.